What's Happening?
The FDA has proposed a new rule to close the GRAS (Generally Recognized as Safe) loophole, which has allowed companies to self-affirm substances as safe without notifying the agency. The proposed rule would require firms to submit a full GRAS notice to the FDA for
new substances, while offering a streamlined process for legacy substances already on the market. This change aims to enhance post-market safety evaluations and reduce regulatory burdens. The proposal will be open for a 120-day comment period before the FDA finalizes the rule. Legal experts anticipate challenges due to the lack of clear congressional authorization for mandatory notifications.
Why It's Important?
The proposed changes could significantly impact the food industry by increasing the regulatory oversight of substances deemed GRAS. Companies may face additional administrative burdens and potential delays in bringing new products to market. The rule aims to ensure that GRAS conclusions are scientifically sound and well-documented, potentially improving food safety. However, the lack of resources for the FDA to handle increased submissions could lead to longer review times, affecting companies' commercial operations. The proposal also raises questions about the FDA's authority to enforce mandatory notifications without explicit congressional approval.
What's Next?
The FDA will review public comments and develop a final rule after the comment period. Companies are advised to prepare for potential mandatory notifications by ensuring their GRAS determinations are well-documented and defensible. Legal challenges are expected, which could delay the implementation of the rule. The outcome of these challenges and any congressional actions to amend the statute will be crucial in determining the future of GRAS regulations. Companies should also monitor state-level actions, such as New York's pending legislation on GRAS reporting.
